42 citations
,
July 1982 in “PubMed” This study found that a low estrogen-containing oral contraceptive normalized hormone levels and improved symptoms in women with polycystic ovary disease, with minimal side effects reported.
74 citations
,
December 1995 in “The Journal of Clinical Endocrinology & Metabolism” This study found that treatment with leuprolide plus cyclic estrogen/progestin may lead to a faster and greater improvement in hirsutism compared to a standard oral contraceptive regimen.
36 citations
,
July 1980 in “Journal of Toxicology and Environmental Health” In this animal study, rats given high doses of ethynylestradiol showed dose-related estrogenic effects, delayed tumor onset in females, and no overall increase in tumor incidence compared to controls.
68 citations
,
May 1991 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” This study found that both cyproterone acetate and spironolactone effectively reduced hair diameter and plasma testosterone levels in hirsute women, with no significant differences between the two treatments.
58 citations
,
February 2018 in “Journal of cosmetic dermatology” This review explores how estrogens influence skin health and attractiveness in women, particularly with aging, but it reports no new clinical findings.
57 citations
,
January 1995 in “The American journal of medicine” This study discusses the use of oral contraceptives as a treatment for hyperandrogenism, showing improvement in hirsutism and acne for many women and possibly providing metabolic benefits with certain formulations.
25 citations
,
August 1989 in “Seminars in reproductive medicine” This article discusses the use of oral contraceptives for treating hyperandrogenism in women, reporting improvement in most patients, especially in reducing new hair growth, but presents no new clinical findings.
16 citations
,
August 1967 in “JAMA” This study reports that diffuse alopecia of the scalp developed in some women during or after using oral contraceptive drugs, suggesting a potential link between the medication and hair loss.
11 citations
,
January 1980 in “PubMed” This article reviews various side effects and concerns related to oral contraceptives, including potential vascular complications and elevated plasma cortisol levels, but reports no new clinical results.
1 citations
,
March 2021 in “medRxiv (Cold Spring Harbor Laboratory)” This study provided insight into unexpected uses and abuse of oral contraceptive pills by Jordanian males, primarily for bodybuilding, as reported by community pharmacists.
1 citations
,
November 2011 in “Open access journal of contraception” This article reviews the role of androgens and oral contraceptives in acne pathogenesis and management but presents no new clinical results.
April 2025 in “La Prensa Medica” This study found that oral contraceptives, particularly those combining ethinyl estradiol with progestins like drospirenone and cyproterone acetate, are effective in treating androgen-related skin conditions such as acne, hirsutism, and androgenetic alopecia by reducing excess androgens and sebum production.
July 2012 in “International Journal of Trichology” This article discusses various aspects of hair and scalp health, ancient philosophical perspectives on hair, and causes of hair disorders in children, without reporting new clinical results.
69 citations
,
February 2002 in “International Journal of Cosmetic Science” This review discusses genetic and nutritional causes of hair loss, highlighting that around 90% of treated men show noticeable hair regrowth with a dual inhibitor, while women's hair loss may improve by correcting iron and l-lysine deficiencies.
61 citations
,
January 2017 in “Human Reproduction Open” This review discusses hormone replacement therapy for women with premature ovarian insufficiency, strongly recommending it for symptom relief and bone protection, but notes a lack of evidence on optimal types and doses.
57 citations
,
December 2018 in “JAMA Surgery” This systematic review suggests that current evidence does not support routinely discontinuing gender-affirming hormone treatments before surgery, especially testosterone and spironolactone, due to limited data on related perioperative risks.
18 citations
,
January 2004 in “Dermatologic Clinics” This article discusses nutritional contributions to hair health and highlights the need for identifying risk factors for deficiencies but reports no new clinical findings.
May 2021 in “Journal of the Endocrine Society” This study found that estradiol transdermal patches helped many MTF patients achieve target estrogen levels, especially those who could not reach these levels with oral therapy and those at higher thrombotic risk.
4 citations
,
May 2025 in “Open Access Journal of Contraception” This study suggests that lower-dose ethinyl estradiol formulations and progestin-only contraceptives may offer safer options for managing PCOS in obese women due to minimal metabolic effects.
September 1999 in “The Journal of The British Menopause Society” This review discusses how menopause and hormone replacement therapy affect skin aging in women but reports no new clinical findings.
January 1986 in “Journal of Steroid Biochemistry” Lower testosterone levels in men may be linked to a higher risk of severe coronary artery disease.
22 citations
,
January 2002 in “Treatments in endocrinology” This review examines the role of androgens in cutaneous disorders and the potential therapeutic effects of different oral contraceptives, noting variations in individual responses and the influence of genetic and local factors but reports no new clinical results.
19 citations
,
December 2021 in “Endocrine Reviews” This review highlights therapeutic options for inducing puberty in males and females with delayed puberty, emphasizing the need for larger trials to establish the best approaches.
14 citations
,
September 2017 in “Clinics in Dermatology” This study highlights that lower testosterone in men and higher testosterone in women are linked to increased risks of metabolic syndrome and type 2 diabetes, with associated skin diseases indicating potential cardiovascular complications.
502 citations
,
February 2008 in “The Journal of Clinical Endocrinology & Metabolism” This review discusses hirsutism management guidelines, recommending androgen testing only for women with abnormal hirsutism scores and advocating for combined therapy approaches depending on severity and underlying conditions, but it reports no new clinical results.
January 2017 in “Elsevier eBooks” Sex hormones affect reproduction, sexual development, and oral health, and it's important for dental practitioners to understand their effects and interactions.
67 citations
,
March 2018 in “The Journal of Clinical Endocrinology & Metabolism” This study reported that estrogen-progestin oral contraceptives, antiandrogens, and insulin sensitizers are more effective than placebo in treating hirsutism in women, with combination therapies generally proving superior to monotherapy.
37 citations
,
February 2007 in “Clinical Obstetrics and Gynecology” This article examines current pharmacologic treatments for PCOS focusing on symptom-specific approaches, particularly the metabolic effects of therapies, but reports no new clinical findings.
21 citations
,
February 2017 in “International Journal of Women's Dermatology” This review discusses the physiology and potential hormonal mechanisms involved in female pattern hair loss, as well as the current hormonal and hormone-modifying treatments available, but reports no new research findings.
18 citations
,
January 2020 in “Journal of Clinical Research in Pediatric Endocrinology” This review discusses the pathophysiology, diagnosis, and management of functional hypothalamic amenorrhea in adolescent girls and reports no new clinical results.